Abstract
Bone and joint infections (BJIs) are often difficult to treat. Staphylococcus spp. is the major pathogen causing these infections, which is often associated with biofilm formation on prosthetic materials. Therapeutic measures are complex, ranging from surgical intervention to initial intravenous and supportive long-term oral antibiotic therapy. The options for oral antimicrobial therapy are limited, mainly due to the resistance profile of the causative pathogen and the unfavourable pharmacodynamic and pharmacokinetic properties of most antibiotics in biofilm. Data analysis over a 5-year period was performed on staphylococci isolated from BJI patients in the Orthopaedic Department of the University Hospital Heidelberg (Heidelberg, Germany) to assess the plausibility of fusidic acid (FA)-based alternative oral treatment regimens. Six percent of BJIs were caused by meticillin-resistant Staphylococcus aureus (MRSA), and multiresistance was common. Over 75% of MRSA in BJIs were resistant to the commonly used rifampicin (RIF)-based combinations. Resistance to FA-based combinations was high. However, over 80% were susceptible to the combination RIF+FA. In coagulase-negative staphylococci, resistance to RIF-based combinations was simil...Continue Reading
References
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·M DrancourtD Raoult
Oct 21, 1999·International Journal of Antimicrobial Agents·J Turnidge
Oct 21, 1999·International Journal of Antimicrobial Agents·B Atkins, T Gottlieb
Jul 11, 2002·Biochemical Pharmacology·Konrad A BodeDietrich Keppler
May 1, 2004·The Journal of Antimicrobial Chemotherapy·Elizabeth S R Darley, Alasdair P MacGowan
Oct 16, 2004·The New England Journal of Medicine·Werner ZimmerliPeter E Ochsner
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Raphael SaginurKaram Ramotar
Nov 26, 2008·Journal of Chemotherapy·K KanellakopoulouE J Giamarellos-Bourboulis
Mar 14, 2009·The Journal of Antimicrobial Chemotherapy·F Kate GouldUNKNOWN MRSA Working Party of the British Society for Antimicrobial Chemotherapy
Mar 23, 2010·Médecine et maladies infectieuses·UNKNOWN Société de Pathologie Infectieuse de Langue Française (SPILF)UNKNOWN Société Française de Rhumatologie (SFR-Rhu)
May 13, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carl N Kraus, Barry W Burnstead
Dec 14, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brad Spellberg, Benjamin A Lipsky
May 23, 2012·International Journal of Antimicrobial Agents·Jiun-Ling WangPo-Ren Hsueh
Nov 2, 2012·Antimicrobial Agents and Chemotherapy·T N PeelP F M Choong
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Sep 28, 2013·The Journal of Antimicrobial Chemotherapy·Baek-Nam KimMyoung-Don Oh
May 24, 2014·The Journal of Antimicrobial Chemotherapy·Dennis NurjadiPhilipp Zanger
Citations
May 20, 2016·Infectious Diseases·Guillaume G AubinStéphane Corvec
Mar 10, 2018·Future Microbiology·Monica BortolinLorenzo Drago
May 2, 2018·Antimicrobial Agents and Chemotherapy·Wafi SialaFrançoise Van Bambeke
Nov 21, 2018·Antimicrobial Agents and Chemotherapy·Werner Zimmerli, Parham Sendi
Dec 18, 2020·Frontiers in Bioengineering and Biotechnology·Jianqiao LiuYujin Tang
May 3, 2021·Antimicrobial Resistance and Infection Control·Bahareh HajikhaniMasoud Dadashi